Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan.
Journal: The oncologist
Published: December 22, 2024
First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors.
Journal: Cancer
Published: November 08, 2024
A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 04, 2024
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
Journal: Journal for immunotherapy of cancer
Published: May 26, 2023
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 01, 2022
Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 30, 2021
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.
Journal: Journal for immunotherapy of cancer
Published: March 16, 2021
A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma.
Journal: Investigational new drugs
Published: April 07, 2020
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
Journal: Cancer chemotherapy and pharmacology
Published: February 24, 2020
Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials.
Journal: Targeted oncology
Published: October 09, 2019
Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations.
Journal: Targeted oncology
Published: February 10, 2018
A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies.
Journal: Targeted oncology
Published: March 31, 2017
Last Updated: 09/26/2026